论文部分内容阅读
目的 :研究 48例Ⅰ期非小细胞肺癌 (NSCLC)p5 3蛋白的表达 ,试图为早期肺癌找到灵敏、特异的指标 ,以指导术后治疗。方法 :收集手术后原发灶的石腊标本及其临床、随访资料 ,以p5 3单抗为探针 ,采用免疫组化S P (streptavidin peroxidase)法检测原发灶p5 3蛋白的表达。结果 :48例Ⅰ期NSCLC患者中 2 3例(47 9% )阳性 ,p5 3(+)组五年生存率为 30 4% (7/ 2 3) ,p5 3(- )组为 72 0 % (18/ 2 5 ) ,χ2 检验P <0 0 1,生存分析log rank检验P <0 0 1;无病生存期明确的 37例患者中p5 3(+)组无病生存率为 40 0 % (6 / 15 ) ,p5 3(- )组无病生存率为 77 3% (17/ 2 2 ) ,χ2 检验P <0 0 5 ,生存分析log rank检验P <0 0 5。结论 :p5 3(+)组的生存期及无病生存期均明显短于p5 3(- )组。免疫组化法检测Ⅰ期NSCLC患者原发灶p5 3蛋白表达具有临床实用价值
Objective: To study the expression of p5 3 protein in 48 cases of stage Ⅰ non-small cell lung cancer (NSCLC), in order to find sensitive and specific indicators for early lung cancer to guide postoperative treatment. Methods: The paraffin specimens of the primary tumor and its clinical and follow-up data were collected. The p5 3 protein was detected by streptavidin peroxidase (SP) immunohistochemical method using p5 3 as a probe. Results: The 48 patients with stage Ⅰ NSCLC had 23 cases (47.9%) positive, the 5-year survival rate of p5 3 (+) group was 30 4% (7/2 3) and that of p5 3 (- (Χ2 test, P <0.01). The survival analysis log rank test (P <0.01); The disease-free survival rate of p5 3 (+) group was 40 0% (6/15) in the p5 3 (-) group, 77 3% (17/2 2) in the p5 3 (-) group, P 0 05 in the χ2 test, and P <0 05 in the survival analysis. Conclusion: The survival and disease-free survival of p5 3 (+) group were significantly shorter than that of p5 3 (-) group. Immunohistochemical detection of stage Ⅰ NSCLC patients with primary p51 protein expression has clinical value